Ketamine vs Classic Psychedelics

Safety first. Neither group should be used outside medical care in the hope of treating a condition. Ketamine can cause dangerously slow breathing, especially with opioids or alcohol. [1] Both groups can cause fear, confusion and unsafe behavior. [2] In an emergency call 911 (US) or your local emergency number; US Poison Help is 1-800-222-1222; in a US mental health crisis call or text 988. This page is education only: no amounts, sourcing or advice to start or stop a medicine.

Evidence labels used here: approved medicine, promising but limited, mixed, insufficient evidence. Where we looked and found nothing usable, we write "Proper evidence not found."

Definitions

• Classic psychedelics (psilocybin, LSD, DMT) mainly act on serotonin 5-HT2A receptors and may bring vivid visions and changes in sense of self. [2]
• Dissociatives (ketamine, PCP) block NMDA receptors, part of the glutamate system, and often make people feel disconnected from their body and surroundings. [2]

Ketamine is therefore not a classic psychedelic. Nor is it natural: it is a compound used as an anesthetic. [1] See dissociatives and classic psychedelics.

Side-by-side

What research shows

• Ketamine family, treatment-resistant depression: esketamine is an approved medicine for adults. [6] Ketamine itself is used off-label. A review of 60 articles found more psychiatric, cardiovascular and neurological side effects than with placebo, but long-term safety was poorly assessed. [7]
• Psilocybin, depression: promising but limited. A 104-person trial found psilocybin reduced depression scores more than niacin over six weeks, with more adverse events. [8] A phase 2 trial of a synthetic psilocybin formulation (233 people with treatment-resistant depression) found the higher single dose reduced depression scores more than a 1-mg control dose at 3 weeks; sustained response at 12 weeks was not supportive, and 77% had adverse events. [9]
• Shared research problem. Strong, obvious effects make it hard to hide who got the drug, so expectation may inflate effects. [10]
• Mechanism. NIDA says scientists suspect some of these substances may cause brain changes that increase how well treatments work, but research is ongoing. [3] A systematic review of brain-network studies found it unclear how central network changes are to the therapeutic potential of classic psychedelics. [11]
• Head-to-head trials of ketamine against psilocybin: Proper evidence not found (our PubMed searches this session did not surface a direct comparison trial).

Risks

• Ketamine: respiratory depression with unsupervised use, bladder and gut problems with long-term heavy use, memory problems. [1]
• Classic psychedelics: fear, anxiety, paranoia; one high-dose study of 18 adults reported extreme fear in 39% during the session. [3] NIDA reports some evidence that psychedelics might trigger schizophrenia-like illness in people with predisposing factors, but little evidence that they cause long-term psychiatric problems for most people. [3]
• Clinical trials report a low rate of serious events for classic psychedelics, about 4% in people with existing neuropsychiatric conditions in one review, though few trials assessed adverse events systematically. [12]

Legal note

No universal winner